Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $16.8 million.

  • Foghorn Therapeutics' Net Cash Flow rose 12062.53% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.2 million, marking a year-over-year increase of 36289.2%. This contributed to the annual value of -$24.9 million for FY2024, which is 18847.88% down from last year.
  • As of Q3 2025, Foghorn Therapeutics' Net Cash Flow stood at $16.8 million, which was up 12062.53% from $13.1 million recorded in Q2 2025.
  • Foghorn Therapeutics' Net Cash Flow's 5-year high stood at $112.5 million during Q1 2022, with a 5-year trough of -$152.4 million in Q2 2022.
  • Moreover, its 5-year median value for Net Cash Flow was $7.1 million (2023), whereas its average is -$102315.8.
  • Within the past 5 years, the most significant YoY rise in Foghorn Therapeutics' Net Cash Flow was 74528.46% (2024), while the steepest drop was 74483.85% (2024).
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Net Cash Flow stood at $43.3 million in 2021, then plummeted by 181.8% to -$35.4 million in 2022, then surged by 128.32% to $10.0 million in 2023, then crashed by 122.17% to -$2.2 million in 2024, then skyrocketed by 853.69% to $16.8 million in 2025.
  • Its Net Cash Flow stands at $16.8 million for Q3 2025, versus $13.1 million for Q2 2025 and $5.6 million for Q1 2025.